Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution
Introduction: Circulating tumor DNA (ctDNA) can be obtained from cell-free DNA (cfDNA) andis a new technique for genotyping, response assessment and prognosis in lymphoma. Methods: Eighteen patients with samples at diagnosis (ctDNA1), after treatment (ctDNA2) and extracted from diagnostic tissue (FF...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924003262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850254913283555328 |
|---|---|
| author | Guilherme Duffles Jersey Heitor da Silva Maués Fernanda Lupinacci Luciana Guilhermino Pereira Elisa Napolitano Ferreira Leandro Freitas Fernanda Niemann Maria Emilia Seren Takahashi Celso Darío Ramos Maria de Lourdes L. Ferrari Chauffaille Irene Lorand-Metze |
| author_facet | Guilherme Duffles Jersey Heitor da Silva Maués Fernanda Lupinacci Luciana Guilhermino Pereira Elisa Napolitano Ferreira Leandro Freitas Fernanda Niemann Maria Emilia Seren Takahashi Celso Darío Ramos Maria de Lourdes L. Ferrari Chauffaille Irene Lorand-Metze |
| author_sort | Guilherme Duffles |
| collection | DOAJ |
| description | Introduction: Circulating tumor DNA (ctDNA) can be obtained from cell-free DNA (cfDNA) andis a new technique for genotyping, response assessment and prognosis in lymphoma. Methods: Eighteen patients with samples at diagnosis (ctDNA1), after treatment (ctDNA2) and extracted from diagnostic tissue (FFPE) were evaluated. Results: In all patients, at least one mutation in cfDNA was detected at diagnosis. CREBBP was the most frequent mutated gene (67 %). In 12 of the 15 patients with complete remission, the mutation attributed to the disease found at diagnosis cleared with treatment. A reduction in the ctDNA was observed after treatment in 14 patients, 12 of whom achieved complete remission. Correlations were found between the ctDNA at diagnosis and total metabolic tumor volume (r = 0.51; p-value = 0.014) and total lesion glycolysis 2.5 (r = 0.47; p-value = 0.024) by PET at diagnosis and between ctDNA at diagnosis and radiomic features of the lesions with the largest standardized uptake value. There was a strong inverse correlation between ΔctDNA1 and ΔSUVmax by PET/CT (r = −0.8788; p-value = 0.002). Conclusion: Analysis of ctDNA and PET/CT in large B-cell lymphoma are complementary data for evaluating tumor burden and tumor clearance after treatment. Analysis of radiomic data might help to identify tumor characteristics and their changes after treatment. |
| format | Article |
| id | doaj-art-d6845f5e9ca84f30ad0ce50df3f055ed |
| institution | OA Journals |
| issn | 2531-1379 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-d6845f5e9ca84f30ad0ce50df3f055ed2025-08-20T01:57:00ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-12-0146S241S24910.1016/j.htct.2024.07.005Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolutionGuilherme Duffles0Jersey Heitor da Silva Maués1Fernanda Lupinacci2Luciana Guilhermino Pereira3Elisa Napolitano Ferreira4Leandro Freitas5Fernanda Niemann6Maria Emilia Seren Takahashi7Celso Darío Ramos8Maria de Lourdes L. Ferrari Chauffaille9Irene Lorand-Metze10University of Campinas, Hematology and Hemotherapy Centre, Hematology, Unicamp, Campinas 13083-878, SP, Brazil; Rede Dor Sao Luiz, Sao Paulo 01401-002, SP, Brazil; Corresponding author at: Rua Carlos Chagas, 480, Cidade Universitária, Campinas CEP: 13083-878, SP, Brazil.University of Campinas, Hematology and Hemotherapy Centre, Hematology, Unicamp, Campinas 13083-878, SP, BrazilFleury Medicina e Saúde, Grupo Fleury, São Paulo 04580-060, SP, BrazilFleury Medicina e Saúde, Grupo Fleury, São Paulo 04580-060, SP, BrazilFleury Medicina e Saúde, Grupo Fleury, São Paulo 04580-060, SP, BrazilDepartment of Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, 13083-888, SP, BrazilUniversity of Campinas, Hematology and Hemotherapy Centre, Hematology, Unicamp, Campinas 13083-878, SP, BrazilGleb Wataghin Institute of Physics, University of Campinas (UNICAMP), Campinas 13083-859, SP, BrazilDivision of Nuclear Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas 13083-888, SP, BrazilFleury Medicina e Saúde, Grupo Fleury, São Paulo 04580-060, SP, BrazilUniversity of Campinas, Hematology and Hemotherapy Centre, Hematology, Unicamp, Campinas 13083-878, SP, BrazilIntroduction: Circulating tumor DNA (ctDNA) can be obtained from cell-free DNA (cfDNA) andis a new technique for genotyping, response assessment and prognosis in lymphoma. Methods: Eighteen patients with samples at diagnosis (ctDNA1), after treatment (ctDNA2) and extracted from diagnostic tissue (FFPE) were evaluated. Results: In all patients, at least one mutation in cfDNA was detected at diagnosis. CREBBP was the most frequent mutated gene (67 %). In 12 of the 15 patients with complete remission, the mutation attributed to the disease found at diagnosis cleared with treatment. A reduction in the ctDNA was observed after treatment in 14 patients, 12 of whom achieved complete remission. Correlations were found between the ctDNA at diagnosis and total metabolic tumor volume (r = 0.51; p-value = 0.014) and total lesion glycolysis 2.5 (r = 0.47; p-value = 0.024) by PET at diagnosis and between ctDNA at diagnosis and radiomic features of the lesions with the largest standardized uptake value. There was a strong inverse correlation between ΔctDNA1 and ΔSUVmax by PET/CT (r = −0.8788; p-value = 0.002). Conclusion: Analysis of ctDNA and PET/CT in large B-cell lymphoma are complementary data for evaluating tumor burden and tumor clearance after treatment. Analysis of radiomic data might help to identify tumor characteristics and their changes after treatment.http://www.sciencedirect.com/science/article/pii/S2531137924003262ctDNALiquid biopsyDiffuse large B-cell lymphoma (DLBCL)LymphomaClone evolutionPET/CT |
| spellingShingle | Guilherme Duffles Jersey Heitor da Silva Maués Fernanda Lupinacci Luciana Guilhermino Pereira Elisa Napolitano Ferreira Leandro Freitas Fernanda Niemann Maria Emilia Seren Takahashi Celso Darío Ramos Maria de Lourdes L. Ferrari Chauffaille Irene Lorand-Metze Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution Hematology, Transfusion and Cell Therapy ctDNA Liquid biopsy Diffuse large B-cell lymphoma (DLBCL) Lymphoma Clone evolution PET/CT |
| title | Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution |
| title_full | Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution |
| title_fullStr | Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution |
| title_full_unstemmed | Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution |
| title_short | Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution |
| title_sort | circulating tumor dna in diffuse large b cell lymphoma analysis of response assessment correlation with pet ct and clone evolution |
| topic | ctDNA Liquid biopsy Diffuse large B-cell lymphoma (DLBCL) Lymphoma Clone evolution PET/CT |
| url | http://www.sciencedirect.com/science/article/pii/S2531137924003262 |
| work_keys_str_mv | AT guilhermeduffles circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT jerseyheitordasilvamaues circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT fernandalupinacci circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT lucianaguilherminopereira circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT elisanapolitanoferreira circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT leandrofreitas circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT fernandaniemann circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT mariaemiliaserentakahashi circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT celsodarioramos circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT mariadelourdeslferrarichauffaille circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution AT irenelorandmetze circulatingtumordnaindiffuselargebcelllymphomaanalysisofresponseassessmentcorrelationwithpetctandcloneevolution |